In the context of gene therapy for treating Alzheimer’s disease, the therapeutic potential of Fgf2 by stimulating NSCs in neurodegenerative disorders has already been demonstrated [133]. This evidence concerns the gene FGF2 and early-onset autosomal dominant Alzheimer disease.